Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.31 -1.71%
EPS Growth %: +30.2%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +30.2%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $16.5 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
